(Q45871441)

English

Treatment of consecutive patients with chronic myeloid leukaemia in the cooperating centres from the Czech Republic and the whole of Slovakia after 2000--a report from the population-based CAMELIA Registry

scientific article published in August 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

17 December 2017

http://europepmc.org/abstract/MED/21535160

Treatment of consecutive patients with chronic myeloid leukaemia in the cooperating centres from the Czech Republic and the whole of Slovakia after 2000--a report from the population-based CAMELIA Registry (English)

1 reference

Europe PubMed Central

17 December 2017

http://europepmc.org/abstract/MED/21535160

0 references

1 reference

based on heuristic

inferred from title

0 references

1 reference

based on heuristic

inferred from title

Ladislav Dušek

13

1 reference

Europe PubMed Central

17 December 2017

http://europepmc.org/abstract/MED/21535160

object named as

Eduard Cmunt

9

0 references

1

object named as

Edgar Faber

0 references

author name string

Edgar Faber

1

1 reference

Europe PubMed Central

17 December 2017

http://europepmc.org/abstract/MED/21535160

Jan Mužík

2

1 reference

Europe PubMed Central

17 December 2017

http://europepmc.org/abstract/MED/21535160

Vladimír Koza

3

1 reference

Europe PubMed Central

17 December 2017

http://europepmc.org/abstract/MED/21535160

Eva Demečková

4

1 reference

Europe PubMed Central

17 December 2017

http://europepmc.org/abstract/MED/21535160

Jaroslava Voglová

5

1 reference

Europe PubMed Central

17 December 2017

http://europepmc.org/abstract/MED/21535160

Ludmila Demitrovičová

6

1 reference

Europe PubMed Central

17 December 2017

http://europepmc.org/abstract/MED/21535160

Juraj Chudej

7

1 reference

Europe PubMed Central

17 December 2017

http://europepmc.org/abstract/MED/21535160

Imrich Markuljak

8

1 reference

Europe PubMed Central

17 December 2017

http://europepmc.org/abstract/MED/21535160

Tomáš Kozák

10

1 reference

Europe PubMed Central

17 December 2017

http://europepmc.org/abstract/MED/21535160

Elena Tóthová

11

1 reference

Europe PubMed Central

17 December 2017

http://europepmc.org/abstract/MED/21535160

Marie Jarošová

12

1 reference

Europe PubMed Central

17 December 2017

http://europepmc.org/abstract/MED/21535160

Karel Indrák

14

1 reference

Europe PubMed Central

17 December 2017

http://europepmc.org/abstract/MED/21535160

publication date

1 August 2011

1 reference

Europe PubMed Central

17 December 2017

http://europepmc.org/abstract/MED/21535160

European Journal of Haematology

1 reference

Europe PubMed Central

17 December 2017

http://europepmc.org/abstract/MED/21535160

87

1 reference

Europe PubMed Central

17 December 2017

http://europepmc.org/abstract/MED/21535160

2

1 reference

Europe PubMed Central

17 December 2017

http://europepmc.org/abstract/MED/21535160

157-168

1 reference

Europe PubMed Central

17 December 2017

http://europepmc.org/abstract/MED/21535160

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2011.01637.X

21 January 2018

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2011.01637.X

21 January 2018

Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2011.01637.X

21 January 2018

Role of allogeneic stem cell transplantation for adult chronic myeloid leukemia in the imatinib era.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2011.01637.X

21 January 2018

Imatinib mesylate versus allogeneic BMT for patients with chronic myeloid leukemia in first chronic phase

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2011.01637.X

21 January 2018

A population study of imatinib in chronic myeloid leukaemia demonstrates lower efficacy than in clinical trials

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2011.01637.X

21 January 2018

Age disparity in the dissemination of imatinib for treating chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2011.01637.X

21 January 2018

Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2011.01637.X

21 January 2018

Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2011.01637.X

21 January 2018

A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2011.01637.X

21 January 2018

Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer program.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2011.01637.X

21 January 2018

"Real-life" results of front-line treatment with Imatinib in older patients (≥ 65 years) with newly diagnosed chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2011.01637.X

21 January 2018

Allogeneic haematopoietic cell transplantation for chronic myelogenous leukaemia in the era of imatinib: a retrospective multicentre study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2011.01637.X

21 January 2018

Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2011.01637.X

21 January 2018

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2011.01637.X

21 January 2018

Clinical trials underestimate the age of chronic myeloid leukemia (CML) patients. Incidence and median age of Ph/BCR-ABL-positive CML and other chronic myeloproliferative disorders in a representative area in Germany

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2011.01637.X

21 January 2018

Drug treatment is superior to allografting as first-line therapy in chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2011.01637.X

21 January 2018

Survival advantage from imatinib compared with the combination interferon- plus cytarabine in chronic-phase chronic myelogenous leukemia: historical comparison between two phase 3 trials

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2011.01637.X

21 January 2018

Identifiers

10.1111/J.1600-0609.2011.01637.X

1 reference

Europe PubMed Central

17 December 2017

http://europepmc.org/abstract/MED/21535160

1 reference

Europe PubMed Central

17 December 2017

http://europepmc.org/abstract/MED/21535160

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45871441&oldid=2093854319"